A citation-based method for searching scientific literature

Rebecca K Senter, Ayan Ghoshal, Adam G Walker, Zixiu Xiang, Colleen M Niswender, P Jeffrey Conn. Curr Neuropharmacol 2016
Times Cited: 6







List of co-cited articles
54 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.
James Maksymetz, Sean P Moran, P Jeffrey Conn. Mol Brain 2017
65
50

Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
50

AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study.
Robert E Litman, Mark A Smith, James J Doherty, Alan Cross, Shane Raines, Lev Gertsik, Stephen R Zukin. Schizophr Res 2016
44
50


Pharmacological agents acting at subtypes of metabotropic glutamate receptors.
D D Schoepp, D E Jane, J A Monn. Neuropharmacology 1999
876
33

Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system.
Luisa Di Menna, Max E Joffe, Luisa Iacovelli, Rosamaria Orlando, Craig W Lindsley, Jèrome Mairesse, Pierre Gressèns, Milena Cannella, Filippo Caraci, Agata Copani,[...]. Neuropharmacology 2018
50
33

The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia.
Branden J Stansley, P Jeffrey Conn. Curr Opin Pharmacol 2018
30
33

Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction.
Adam G Walker, Cody J Wenthur, Zixiu Xiang, Jerri M Rook, Kyle A Emmitte, Colleen M Niswender, Craig W Lindsley, P Jeffrey Conn. Proc Natl Acad Sci U S A 2015
61
33


Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy.
Samuel A Barnes, Douglas J Sheffler, Svetlana Semenova, Nicholas D P Cosford, Anton Bespalov. Biol Psychiatry 2018
19
33

Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies.
Hiba Salih, Ion Anghelescu, Iva Kezic, Vikash Sinha, Eef Hoeben, Luc Van Nueten, Heidi De Smedt, Peter De Boer. J Psychopharmacol 2015
32
33

Potential antipsychotic and extrapyramidal effects of (R,S)-3,4-dicarboxyphenylglycine [(R,S)-3,4-DCPG], a mixed AMPA antagonist/mGluR8 agonist.
Krystyna Ossowska, Małgorzata Pietraszek, Jadwiga Wardas, Stanisław Wolfarth. Pol J Pharmacol 2004
22
33

The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT₁A signalling.
Joanna M Wierońska, Francine C Acher, Anna Sławińska, Piotr Gruca, Magdalena Lasoń-Tyburkiewicz, Mariusz Papp, Andrzej Pilc. Psychopharmacology (Berl) 2013
28
33

Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS.
Shen Yin, Meredith J Noetzel, Kari A Johnson, Rocio Zamorano, Nidhi Jalan-Sakrikar, Karen J Gregory, P Jeffrey Conn, Colleen M Niswender. J Neurosci 2014
80
33

In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists.
Gentaroh Suzuki, Naohiro Tsukamoto, Hiroshi Fushiki, Aki Kawagishi, Masayuki Nakamura, Hideki Kurihara, Morihiro Mitsuya, Mitsuru Ohkubo, Hisashi Ohta. J Pharmacol Exp Ther 2007
104
33

Identification of a serotonin/glutamate receptor complex implicated in psychosis.
Javier González-Maeso, Rosalind L Ang, Tony Yuen, Pokman Chan, Noelia V Weisstaub, Juan F López-Giménez, Mingming Zhou, Yuuya Okawa, Luis F Callado, Graeme Milligan,[...]. Nature 2008
550
33


Role of Metabotropic Glutamate Receptors in Neurological Disorders.
Rosalia Crupi, Daniela Impellizzeri, Salvatore Cuzzocrea. Front Mol Neurosci 2019
63
33

Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants.
Jason M Uslaner, Sean M Smith, Sarah L Huszar, Rashida Pachmerhiwala, Richard M Hinchliffe, Joshua D Vardigan, Pete H Hutson. Psychopharmacology (Berl) 2009
25
33


The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents.
Anna Sławińska, Joanna M Wierońska, Katarzyna Stachowicz, Marcin Marciniak, Magdalena Lasoń-Tyburkiewicz, Piotr Gruca, Mariusz Papp, Magdalena Kusek, Krzysztof Tokarski, Darío Doller,[...]. Br J Pharmacol 2013
36
33

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
780
33


A Review of Molecular Imaging of Glutamate Receptors.
Jong-Hoon Kim, János Marton, Simon Mensah Ametamey, Paul Cumming. Molecules 2020
7
33



Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia.
Melanie J Robbins, Kathryn R Starr, Andy Honey, Ellen M Soffin, Claire Rourke, Gareth A Jones, Fiona M Kelly, Jay Strum, Rosemary A Melarange, Andy J Harris,[...]. Brain Res 2007
39
33

Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016.
Fiona J Charlson, Alize J Ferrari, Damian F Santomauro, Sandra Diminic, Emily Stockings, James G Scott, John J McGrath, Harvey A Whiteford. Schizophr Bull 2018
263
33

Increased measures of anxiety and weight gain in mice lacking the group III metabotropic glutamate receptor mGluR8.
Robert M Duvoisin, Connie Zhang, Timothy F Pfankuch, Heather O'Connor, Jacqueline Gayet-Primo, Salma Quraishi, Jacob Raber. Eur J Neurosci 2005
65
33

Control of neuronal excitability by Group I metabotropic glutamate receptors.
Ana Maria Bernal Correa, Jennifer Diniz Soares Guimarães, Everton Dos Santos E Alhadas, Christopher Kushmerick. Biophys Rev 2017
7
33

Reduced Prepulse Inhibition as a Biomarker of Schizophrenia.
Auxiliadora Mena, Juan C Ruiz-Salas, Andrea Puentes, Inmaculada Dorado, Miguel Ruiz-Veguilla, Luis G De la Casa. Front Behav Neurosci 2016
82
33

Group II Metabotropic Glutamate Receptors: Role in Pain Mechanisms and Pain Modulation.
Mariacristina Mazzitelli, Enza Palazzo, Sabatino Maione, Volker Neugebauer. Front Mol Neurosci 2018
17
33


Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists.
José L Moreno, Terrell Holloway, Laura Albizu, Stuart C Sealfon, Javier González-Maeso. Neurosci Lett 2011
126
33

The effect of mGlu8 deficiency in animal models of psychiatric diseases.
M Fendt, H Bürki, S Imobersteg, H van der Putten, K McAllister, J C Leslie, D Shaw, C Hölscher. Genes Brain Behav 2010
34
33

Negative Allosteric Modulators of mGlu7 Receptor as Putative Antipsychotic Drugs.
Paulina Cieślik, Monika Woźniak, Katarzyna Kaczorowska, Piotr Brański, Grzegorz Burnat, Agnieszka Chocyk, Bartosz Bobula, Piotr Gruca, Ewa Litwa, Agnieszka Pałucha-Poniewiera,[...]. Front Mol Neurosci 2018
15
33

Neurochemical and behavioral studies on the 5-HT1A-dependent antipsychotic action of the mGlu4 receptor agonist LSP4-2022.
Monika Woźniak, Krystyna Gołembiowska, Karolina Noworyta-Sokołowska, Francine Acher, Paulina Cieślik, Magdalena Kusek, Krzysztof Tokarski, Andrzej Pilc, Joanna M Wierońska. Neuropharmacology 2017
18
33

Deleterious GRM1 mutations in schizophrenia.
Mohammed Akli Ayoub, Dora Angelicheva, David Vile, David Chandler, Bharti Morar, Juleen A Cavanaugh, Peter M Visscher, Assen Jablensky, Kevin D G Pfleger, Luba Kalaydjieva. PLoS One 2012
42
33

A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.
Michael A Benneyworth, Zixiu Xiang, Randy L Smith, Efrain E Garcia, P Jeffrey Conn, Elaine Sanders-Bush. Mol Pharmacol 2007
126
33


ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization.
Mikhail Kalinichev, Mélanie Rouillier, Francoise Girard, Isabelle Royer-Urios, Bruno Bournique, Terry Finn, Delphine Charvin, Brice Campo, Emmanuel Le Poul, Vincent Mutel,[...]. J Pharmacol Exp Ther 2013
64
33

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
John H Krystal, Walid Abi-Saab, Edward Perry, D Cyril D'Souza, Nianjin Liu, Ralitza Gueorguieva, Lisa McDougall, Tracy Hunsberger, Aysenil Belger, Louise Levine,[...]. Psychopharmacology (Berl) 2005
205
33


Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders.
Mikhail Kalinichev, Emmanuel Le Poul, Christelle Boléa, Françoise Girard, Brice Campo, Massimiliano Fonsi, Isabelle Royer-Urios, Susan E Browne, Jason M Uslaner, Matthew J Davis,[...]. J Pharmacol Exp Ther 2014
47
33

Presynaptic mGlu7 receptors control GABA release in mouse hippocampus.
Maria Summa, Silvia Di Prisco, Massimo Grilli, Cesare Usai, Mario Marchi, Anna Pittaluga. Neuropharmacology 2013
47
33



An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia.
Darrick T Balu, Yan Li, Shunsuke Takagi, Kendall Taylor Presti, Teniel S Ramikie, Jerri M Rook, Carrie K Jones, Craig W Lindsley, P Jeffrey Conn, Vadim Y Bolshakov,[...]. Neuropsychopharmacology 2016
40
33

Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways.
L Iacovelli, V Bruno, L Salvatore, D Melchiorri, R Gradini, A Caricasole, E Barletta, A De Blasi, F Nicoletti. J Neurochem 2002
100
33



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.